Last reviewed · How we verify
NCT05609864: GAME-OvBLOC
Drug Wastage : Observational Study in the Operating Rooms of France
trial testing Quantification of injectable drugs wastage in Drug Use in 3,763 participants. Completed in 20 July 2023.
20 July 2023
Quick facts
| Lead sponsor | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,763 |
| Start date | 6 April 2023 |
| Primary completion | 20 July 2023 |
| Estimated completion | 20 July 2023 |
| Sites | 83 locations across Guadeloupe, France, Monaco, Mayotte |
Drugs / interventions tested
- Quantification of injectable drugs wastage
Conditions studied
- Drug Use — all drugs for Drug Use →
Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Who can join
Eligibility, any sex, with Drug Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Environmental awareness is leading medical field to question its responsibility and possibilities for action. Drug residues can have a major environmental impact as per their bioaccumulation, toxicity and persistence characteristics, depending on where they are discarded. In France, drug residues should be disposed of by incineration, but in practice this is not systematic. Moreover, data on drug wastage in the operating rooms by anesthesia department are rare. The GAME-OvBLOC observational study aim to evaluate drug wastage in the operating rooms by anesthesia department in France and to propose ways of improving health care practices.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05609864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Drug Use
Currently open trials in the same condition.
- NCT07326748 — Lakota Family Acceptance Project · NA · recruiting
- NCT05776316 — Harm Reduction Services · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT05380765 — Developing a Positive Approach to Substance Use Prevention in North American Indian Adolescents · NA · recruiting
- NCT06405490 — NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC · Phase 2 · recruiting
Other Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer trials
Trials by the same sponsor.
- NCT07355582 — Injury Incidence, Severity and Burden in Elite Youth Rugby Players · recruiting
- NCT06865053 — Screening for Heart Failure in General Medicine Consultations · completed
- NCT06863246 — Postural Control in Chronic Obstructive Pulmonary Disease · completed
- NCT06871670 — Force Control in Chronic Obstructive Pulmonary Disease · completed
- NCT06857396 — Tracheal Exposure Without Tracheostomy Completion in Trans-oral Robotic Oncologic Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05609864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing